Drug discovery for polycystic kidney disease

Acta Pharmacologica Sinica

Volumn 32, Issue 6, 2011, Pages 805-816

  Sun, Ying ^a   Zhou, Hong ^a   Yang, Bao Xue ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

animal model; candidate drugs; drug discovery; kidney; polycystic kidney disease

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EKI 569; ENZYME ACTIVATOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MOZAVAPTAN; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; OCTREOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE; PHOSPHODIESTERASE ACTIVATOR; PROTEIN INHIBITOR; RAF PROTEIN; RAF PROTEIN INHIBITOR; ROSIGLITAZONE; SOMATOSTATIN; SORAFENIB; TOLVAPTAN; TRANSMEMBRANE CONDUCTANCE REGULATOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; EPITHELIUM; HUMANS; POLYCYSTIC KIDNEY DISEASES; TRPP CATION CHANNELS;

EID: 79958126807     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.29     Document Type: Conference Paper

References (121)

1. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Biol 2010;191:701-10.
2. Torres VE. Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis 2010;17:190-204.
3. Qian F, Watnick TJ, Onuchic LF, Germino GG. The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 1996;87:979-87. (Pubitemid 26427982)
4. Wilson P. Molecular and cellular aspects of polycystic kidney disease. N Engl J Med 2004;350:151-64.
5. Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, et al. Comprehensive molecular diagnostics in auto somal dominant polycystic kidney disease. J Am Soc Nephrol 2007;18:2143-60. (Pubitemid 47041080)
6. Geng L, Segal Y, Peissel B, Deng N, Pei Y, Carone F, et al. Identi fica tion and localization of polycystin, the PKD1 gene product. J Clin Invest 1996;98:2674-82. (Pubitemid 26427391)
7. International Polycystic Kidney Disease Consortium. Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell 1995;81:289-98.
8. Cai Y, Maeda Y, Cedzich A, Torres VE, Wu GQ, Hayashi T, et al. Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem 1999;274:28557-65.
9. Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R, et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 2002;4:191-7. (Pubitemid 34218192)
10. Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 2002;12: R378-80. (Pubitemid 34689219)
11. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are colocalized in renal cilia. J Am Soc Nephrol 2002;13:2508-16.
12. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, Tsiokas L, et al. Co-assembly of polycystin-1 and-2 produces unique cationpermeable currents. Nature 2000;408:990-4. (Pubitemid 32101647)
13. Wu G, Tian X, Nishimura S, Markowitz GS, D'Agati V, Park JH, et al. Trans-heterozygous Pkd1 and Pkd2 mutations modify expression of polycystic kidney disease. Hum Mol Genet 2002;11:1845-54.
14. Harris PC, Rossetti S. Molecular genetics of autosomal recessive polycystic kidney disease. Mol Genet Metab 2004;81:75-85. (Pubitemid 38096373)
15. Nadasdy T, Laszik Z, Lajoie G, Blick KE, Wheeler DE, Silva FG. Proliferative activity of cyst epithelium in human renal cystic diseases. J Am Soc Nephrol 1995;5:1462-8.
16. Trudel M, D'Agati V, Costantini F. C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 1991;39:665-71.
17. MacKay K, Striker LJ, Pinkert CA, Brinster RL, Striker GE. Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40. Kidney Int 1987;32:827-37. (Pubitemid 18015513)
18. Schaffner DL, Barrios R, Massey C, Banez EI, Ou CN, Rajagopalan S, et al. Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 1993;142:1051-60. (Pubitemid 24060581)
19. Metcalf D, Mifsud S, Di Rago L, Nicola NA, Hilton DJ, Alexander WS. Polycystic kidneys and chronic inflammatory lesions are the delayed consequences of loss of the suppressor of cytokine signaling-1 (SOCS-1). Proc Natl Acad Sci U S A 2002;99:943-8. (Pubitemid 34106615)
20. Du J, Wilson PD. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Physiol 1995;269: C487-95.
21. Yamaguchi T, Pelling JC, Ramaswamy NT. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000;57:1460-71. (Pubitemid 30207906)
22. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004;279:40419-30. (Pubitemid 39287631)
23. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, et al. PKD1 induces p21 (waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002;109:157-68. (Pubitemid 34518255)
24. Grantham JJ, Ye M, Davidow C, Holub BJ, Sharma M. Evidence for a potent lipid secretagogue in the cyst fluids of patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;6:1242-9.
25. Chatterjee S, Shi WY, Wilson P, Mazumdar A. Role of lactosylceramide and MAP kinase kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 1996;37:1334-44. (Pubitemid 26239088)
26. Torres, VE. Apoptosis in cystogenesis: hands on or hands off? Kidney Int 1999;55:334-5. (Pubitemid 29004268)
27. Davidow CJ, Maser RL, Rome LA, Calvet JP, Grantham JJ. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996;50:208-18. (Pubitemid 26323715)
28. - secretion, and renal cyst growth: a study using CFTR inhibitors. Kidney Int 2004;66:1926-38. (Pubitemid 41094317)
29. Sullivan LP, Wallace DP, Grantham JJ. Epithelial transport in polycystic kidney disease. Physiol Rev 1998;78:1165-91. (Pubitemid 28491952)
30. Brill SR, Ross KE, Davidow CJ, Ye M, Grantham JJ, Caplan MJ. Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc Natl Acad Sci U S A 1996;93:10206-11. (Pubitemid 26314600)
31. Sweeney WE, Avner ED, Elmer HL, Cotton CU. CFTR is required for cAMP-dependent: In vitro renal cyst formation. J Am Soc Nephrol 1998;9:38A.
32. O'Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis 1998;32:976-83. (Pubitemid 28551160)
33. Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323-6. (Pubitemid 37279858)
34. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004;10:363-4. (Pubitemid 38508512)
35. Devuyst O, Burrow CR, Smith BL, Agre P, Knepper MA, Wilson PD. Expression of aquaporins-1 and-2 during nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol 1996;271: F169-83.
36. Gattone VH 2nd, Maser RL, Tian C, Rosenberg JM, Branden MG. Develop mental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 1999;24:309-18. (Pubitemid 29211795)
37. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005;67:1234-47. (Pubitemid 40463100)
38. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are colocalized in renal cilia. J Am Soc Nephrol 2002;13:2508-16.
39. Ibraghimov-Beskrovnaya O, Bukanov NO, Donohue LC, Dackowski WR, Klinger KW, Landes GM. Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1. Hum Mol Genet 2000;9:1641-9. (Pubitemid 30427001)
40. Bukanov NO, Husson H, Dackowski WR, Lawrence BD, Clow PA, Roberts BL, et al. Functional polycystin-1 expression is developmental ly regulated during epithelial morphogenesis in vitro: downregulation and loss of membrane localization during cysto genesis. Hum Mol Genet 2002;11:923-36. (Pubitemid 34449780)
41. Roitbak T, Ward CJ, Harris PC, Bacallao R, Ness SA, Wandinger-Ness A. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells. Mol Biol Cell 2004;15:1334-46. (Pubitemid 38316239)
42. Wilson PD, Geng L, Li X, Burrow CR. The PKD1 gene product, "polycystin-1", is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia. Lab Invest 1999;79:1311-23. (Pubitemid 29489454)
43. Hyink DP, Burrow CR, Bloswick B, Wilson PD. Reversal of the ADPKD epithelial cell decreased motility phenotype by lithium. J Am Soc Nephrol 2000;11:392A.
44. Lo SH, Yu QC, Degenstein L, Chen LB, Fuchs E. Progressive kidney degeneration in mice lacking tensin. J Cell Biol 1997;136:1349-61. (Pubitemid 27421920)
45. Shannon MB, Miner JH. Insertional mutation in laminin alpha 5: a new mouse model for polycystic kidney disease. J Am Soc Nephrol 2004;15:652A.
46. van Dijk MA, Kamper AM, van Veen S, Souverijn JH, Blauw GJ. Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2152-7. (Pubitemid 33062136)
47. Praetorius HA, Spring KR. Bending the MDCK cell primary cilium increases intracellular calcium. J Membr Biol 2001;184:71-9. (Pubitemid 33016173)
48. Nauli SM, Alenghat FJ, Luo Y, Caniams E, Vassilev P, Li X, et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003;33:129-37. (Pubitemid 36177063)
49. Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004;15:2528-36. (Pubitemid 41103359)
50. Otto EA, Schermer B, Obara T, O'Toole JF, Hiller KS, Ruf RG, et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of the primary cilia and left-right axis determination. Nat Genet 2003;34:413-20. (Pubitemid 36935334)
51. Robert A, Margall-Ducos G, Guidotti JE, Bregerie O, Celati C, Brechot C, et al. The intraflagellar transport component IFT88/polaris is a centrosomal protein regulating G1-S transition in non-ciliated cells. J Cell Sci 2007;120:628-37. (Pubitemid 46437897)
52. Li X, Luo Y, Starremans PG, McNamara CA, Pei Y, Zhou J. Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat Cell Biol 2005;7:1202-12.
53. Balkovetz DF. Hepatocyte growth factor and Madin-Darby canine kidney cells: in vitro models of epithelial cell movement and morphogenesis. Microsc Res Tech 1998;43:456-63. (Pubitemid 28565792)
54. - co-transporter-dependent cystic dilation. J Am Soc Nephrol 2006;17:3424-37. (Pubitemid 44865285)
55. Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS. Smallmolecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:1300-10.
56. Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 2008;17:1505-16. (Pubitemid 351737156)
57. Shao X, Somlo S, Igarashi P. Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. J Am Soc Nephrol 2002;13:1837-46. (Pubitemid 34700608)
58. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 2002;110:1651-8. (Pubitemid 35424243)
59. Guay-Woodford LM. Murine models of polycystic kidney disease: molecular and therapeutic insights. Am J Physiol Renal Physiol 2003;285: F1034-49. (Pubitemid 37421039)
60. Pritchard L, Sloane-Stanley JA, Sharpe JA, Aspinwall R, Buckle V, Strmecki L, et al. A human PKD1 transgene generates functional polycystin-1 mice and is associated with a cystic phenotype. Human Mol Genet 2000;9:2617-27.
61. Atala A, Freeman MR, Mandell J, Beier DR. Juvenile cystic kidneys (jck): a new mouse mutation which causes polycystic kidneys. Kidney Int 1993;43:1081-5. (Pubitemid 23137093)
62. Liu S, Lu W, Obara T, Kuida S, Lehoczky J, Dewar K, et al. A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish. Development 2002;129:5839-46. (Pubitemid 36054625)
63. Sommardahl C, Woychik R, Sweeney W, Avner E, Wilkinson J. Efficacy of taxol in the orpk mouse model of polycystic kidney disease. Pediatr Nephrol 1997;11:728-33. (Pubitemid 27520539)
64. Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, et al. Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. Kidney Int 2004;66:1766-73. (Pubitemid 41094300)
65. Zafar I, Belibi FA, He Z, Edelstein CL. Edelstein long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease. Nephrol Dial transplant 2009;24:2349-53.
66. Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats. Kidney Int 2003;64:1573-9. (Pubitemid 37323685)
67. Dai B, Liu Y, Mei C, Fu L, Xiong X, Zhang Y, et al. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats. Clin Sci 2010;119:323-33.
68. Bihoreau M, Ceccherini I, Browne J, Kranzlin B, Romeo G, Lathrop GM, et al. Location of the first genetic locus, PKDr1, controlling autosomal dominant polycystic kidney disease in Han:SPRD cy/-rat. Hum Mol Gen 1997;6:609-13. (Pubitemid 27142113)
69. Gretz N, Ceccherini I, Kranzlin B, Kloting I, Devoto M, Rohmeiss P, et al. Gender-dependent disease severity in autosomal polycystic kidney disease of rats. Kidney Int 1995;48:496-500.
70. Nakanishi K, Sweeney WE Jr, Macrae Dell K, Cotton CU, Avner ED. Role of CFTR in autosomal recessive polycystic kidney disease. J Am Soc Nephrol 2001;12:719-25. (Pubitemid 32246700)
71. Wang X, Gattone VH 2nd, Harris PC, Torres VE. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 2005;16:846-51. (Pubitemid 41710293)
72. Gattone VH, Kinne Q, Torres VE. Efficacy of OPC-41061 in the treatment of murine nephronophthisis. J Am Soc Nephrol 2005;16:138A.
73. Wang S, Gattone VH, Somlo S, Harris PC, Torres VE. Effectiveness of OPC-41061 on polycystic kidney disease development in Pkd2WS25/-. J Am Soc Nephrol 2005;16:361A.
74. Grantham JJ, Chapman AB, Torres VE, Ouyang J, Shoaf SE, Czerwiec FS. Acute and chronic osmostasis after vasopressin V2 receptor inhibi tion with tolvaptan in ADPKD. J Am Soc Nephrol 2005;16:361A.
75. Torres VE, Wang X, Ward CJ, Grantham JJ, Chapman AB, Ouyang J, et al. Urine aquaporin 2 and cyclic AMP responses to tolvaptan administration in autosomal dominant kidney disease. J Am Soc Nephrol 2005;16:361A.
76. Chapman AB, Torres VE, Grantham JJ, Shoaf SS, Ouyang JJ, Czerwiec FS. A phase IIB pilot study of the safety and efficacy of tolvaptan, a vaso pressin V2 receptor antagonist (V2RA) in patients with ADPKD. J Am Soc Nephrol 2005;16:68A.
77. Cao Z, Cooper ME. Role of angiotensin II in tubulointerstitial injury. Semin Nephrol 2001;21:554-62. (Pubitemid 33091937)
78. Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemo dynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 2007;293: F854-9. (Pubitemid 47403356)
79. Kennefick TM, Al-Nimri MA, Oyama TT, Thompson MM, Kelly FJ, Chapman JG, et al. Hypertension and renal injury in experimental polycystic kidney disease. Kidney Int 1999;56:2181-90. (Pubitemid 30004747)
80. Schrier R, McFann K, Johnson A, Chapman A, Edelstein C, Brosnahan G, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733-9. (Pubitemid 34700597)
81. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, et al. The HALT polycystic kidney disease trials: design and implementation. Cin J Am Soc Nephrol 2010;5:102-9.
82. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int 2000;57:33-40. (Pubitemid 30227751)
83. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxi some proliferator-activated receptor gamma agonists. Lancet Oncol 2004;5:419-29. (Pubitemid 38878045)
84. Liu Y, Dai B, Fu L, Jia J, Mei C. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells. Basic Clin Pharmacol Toxicol 2010;106:523-30.
85. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′, 5′-cyclic mono phosphate. Gastroenterology 2007;132:1104-16. (Pubitemid 46440866)
86. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206-16. (Pubitemid 43181378)
87. Kusano E, Yoshida I, Takeda S, Homma S, Yusufi AN, Dousa TP, et al. Nephron distribution of total low Km cyclic AMP phosphodiesterase in mouse, rat and rabbit kidney. Tohoku J Exp Med 2001;193:207-20. (Pubitemid 33617022)
88. Cheng J, Thompson MA, Walker HJ, Homma S, Yusufi AN, Dousa TP, et al. Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4. Am J Physiol Renal Physiol 2004;287: F940-53. (Pubitemid 39391091)
89. Wang X, Ward CJ, Harris PC, Torres VE. Cyclic nucleotide signaling in polycystic kidney disease. Kidney Int 2010;77:129-40
90. Sweeney WE Jr, von Vigier RO, Frost P, Avner ED. Src inhibition ameliorates polycystic kidney disease. J Am Soc Nephrol 2008;19:1331-41.
91. Yamaguchi T, Reif GA, Calvet JP, Wallace DP. Sorafenib inhibits cAMP-depend ent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. Am J Physiol Renal Physiol 2010;299: F944-51.
92. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
93. Omori S, Hida M, Fujita H, Takahashi H, Tanimura S, Kohno M, et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol 2006;17:1604-14. (Pubitemid 43794663)
94. Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 2008;17:1505-16. (Pubitemid 351737156)
95. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006;103:5466-71.
96. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB, et al. Polycystin-1 regulates extracellular signal-regulated kinase-depend-ent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 2009;29:2359-71.
97. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84. (Pubitemid 43199434)
98. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90. (Pubitemid 351758225)
99. Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:830-40.
100. Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, Galietta LJ. Altered channel gating mechanism for CFTR inhibition by a high affinity thiazolidinone blocker. FEBS Lett 2004;558:52-6. (Pubitemid 38167409)
101. Sonawane ND, Muanprasat C, Nagatani R Jr, Song Y, Verkman AS. In vivo pharmacology and antidiarrheal efficacy of a thiazolidinone CFTR inhibitor in rodents. J Pharm Sci 2004;94:134-43. (Pubitemid 40116377)
102. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006;444:949-52. (Pubitemid 46025010)
103. Genzyme Corporation, Framingham, Massachusetts. Targeting dysregulated cell cycle and apoptosis for polycystic kidney disease therapy. Cell Cycle 2007;6:776-9.
104. Park JY, Schutzer WE, Lindsley JN, Bagby SP, Oyama TT, Anderson S, et al. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol 2007;8:12.
105. Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, et al. A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 2008;14:863-8.
106. Lee DF, Kuo HP, Chen CT, Hsu JM, Chou CK, Wei Y, et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007;130:440-55. (Pubitemid 47198298)
107. Bieberich E. Integration of glycosphingolipid metabolism and cellfate decisions in cancer and stem cells: review and hypothesis. Glycoconj J 2004;21:315-27 (Pubitemid 39434560)
108. Natoli TA, Smith LA, Rogers KA, Wang B, Komarnitsky S, Budman Y, et al. Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models. Nat Med 2010;16:788-92.
109. Rankin CA, Suzuki K, Itoh Y, Ziemer DM, Grantham JJ, Calvet JP, et al. Matrix metalloproteinases and TIMPS in cultured C57BL/6Jcpk kidney tubules. Kidney Int 1996;50:835-44. (Pubitemid 26302672)
110. Nakamura T, Ushiyama C, Suzuki S, Ebihara I, Shimada N, Koide H. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am J Nephrol 2000;20:32-6. (Pubitemid 30047867)
111. Obermuller N, Morente N, Kranzlin B, Gretz N, Witzgall R. A possible role for metalloproteinases in renal cyst development. Am J Physiol Renal Physiol 2001;280: F540-50.
112. Gile RD, Cowley BD Jr, Gattone VH 2nd, O'Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J kidney Dis 1995;26:501-7.
113. Limura O, Vrtovsnik F, Terzi F, Friedlander G. HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture. Kidney int 1997;52:962-72. (Pubitemid 27435829)
114. Namli S, Oflaz H, Turgut F, Alisir S, Tufan F, Ucar A, et al. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren Fail 2007;29:55-9.
115. Fassett RG, Coombes JS, Packham D, Fairley KF, Kincaid-Smith P. Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease. Scand J Urol Nephrol 2010;44:56-61.
116. Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A 2007;104:4389-94. (Pubitemid 47186236)
117. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999;274:13451-5.
118. Liu H, Liu ZH, Chen ZH, Yang JW, Li LS. Triptolide: a potent inhibitor of NF-kappa B in T-lymphocytes. Acta Pharmacol Sin 2000;21:782-6.
119. Leuenroth SJ, Bencivenga N, Igarashi P, Somlo S, Crews CM. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 2008;19:1659-62.
120. Leuenroth SJ, Bencivenga N, Chahboune H, Hyder F, Crews CM. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant 2010;25:2187-94.
121. Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, et al. Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 2011;654:92-9.